Costs and cost-effectiveness of type 2 diabetes management in Sub-Saharan Africa: a systematic review
Abstract
BACKGROUND: Type 2 Diabetes (T2D) is rapidly increasing in Sub-Saharan Africa (SSA), with related health and financial implications. Knowledge of the costs and cost-effectiveness of managing diabetes is needed to increase awareness, improve resource allocation and enhance the use of evidence-based decision-making. Accordingly, this study sought to synthesise and critically review evidence on the costs and cost-effectiveness of managing T2D in Sub-Saharan Africa (SSA). METHODS: A systematic search was conducted in multiple databases, including PubMed-Medline, Africa-Wide Information, Web of Science, Cochrane Library, CINAHL, Scopus, and Google Scholar, to identify studies published between January 2010 and December 2023; the searches were updated in June 2024. All cost data were converted to 2024 United States dollars (US$) using appropriate inflation adjustments and exchange rates. The review protocol was registered with PROSPERO (CRD42022300580). RESULTS: The search yielded 4137 unique abstracts, and 18 studies were included for review, most originating from Nigeria. Most studies assessed costs from a provider perspective, focusing on direct medical costs (e.g., outpatient consultations, medications, diagnostic and monitoring tests, and follow-up care). Reported costs of T2D management were substantial across settings. Annual costs ranged from US$337.50 for basic medical care of uncomplicated T2D to US$2330.74 in total provider cost per patient. The highest burden was…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.